Recently, the China Healthcare Innovation and Pharmaceutical Summit (CHIPS 2026), focused on investment, financing, and licensing transactions in innovative drugs and medical devices, was successfully held with strong industry engagement. The summit brought together representatives from biopharmaceutical companies, investment institutions, and industry experts to explore emerging opportunities in industry innovation and capital collaboration, with discussions spanning industry development, global expansion, investment and financing, and licensing transactions.

At Session 7-2: AI Innovation Forum, Dr. Michael Chen delivered a keynote presentation titled "From Models to CMC Implementation: How AI Can Overcome Engineering Bottlenecks in Biologics Development."

The value of AI in biologics R&D extends beyond enhancing model capabilities. More importantly, it lies in translating algorithmic innovation into engineering solutions that are verifiable, executable, and scalable—truly advancing AI from technological exploration to real-world industrial applications.

Dr. Chen also joined a panel discussion titled "Behind the Deals: Capital Strategies and Lessons Learned from License-out and NewCo Transactions."

Together with representatives from investment institutions, biopharmaceutical companies, and the financial sector, he exchanged perspectives on License-out transaction models, NewCo structuring and implementation, cross-border capital operations, and the global expansion of innovative therapeutics.

As China's innovative drug industry continues to strengthen its global competitiveness, License-out and NewCo models have become important pathways for biopharmaceutical companies to expand into international markets and unlock the value of their innovations.